MYCN and neuroblastoma: Of note, the first evidence on the role of this enzyme as a key molecule in the progression of MYCN-amplified neuroblastoma dates back to the early 1990s when several studies in different NB mouse models were employed [58–62] More recently, considering the potential implication of this gene on the clinical management of NB, Novak and colleagues [63] hypothesized that the identification of its genetic variations may have significant impact during development of the recurrent or progressive disease.